| Identification | Back Directory | [Name]
ovalicin | [CAS]
19683-98-8 | [Synonyms]
SL-1846
ovalicin
Graphinone
7-hydroxy-8-methoxy-7-[2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-4-oxaspiro[2.5]octan-2-one
(3S)-4β-[(2S,3R)-2-Methyl-3-(3-methyl-2-butenyl)oxiranyl]-4α-hydroxy-5α-methoxy-1-oxaspiro[2.5]octan-6-one
(3S)-4α-Hydroxy-4-[(2S)-2-methyl-3β-(3-methyl-2-butenyl)oxirane-2α-yl]-5α-methoxy-1-oxaspiro[2.5]octane-6-one
1-Oxaspiro[2.5]octan-6-one, 4-hydroxy-5-methoxy-4-[(2S,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-, (3S,4R,5S)- | [Molecular Formula]
C16H24O5 | [MDL Number]
MFCD01710325 | [MOL File]
19683-98-8.mol | [Molecular Weight]
296.36 |
| Chemical Properties | Back Directory | [Melting point ]
94-95 °C | [Boiling point ]
443.8±45.0 °C(Predicted) | [density ]
1.21±0.1 g/cm3(Predicted) | [pka]
13.67±0.40(Predicted) | [Cosmetics Ingredients Functions]
ANTI-SEBORRHEIC
ANTIMICROBIAL | [LogP]
-0.136 (est) |
| Hazard Information | Back Directory | [Uses]
Ovalicin is a potent angiogenesis inhibitor. Ovalicin can be used for the preparation of targeting ubiquitination composition libraries which can be used to identify proteins involved in a predetermined function of cells[1]. | [References]
[1] Raymond J, et al. Proteolysis targeting chimeric pharmaceutical. Patent. WO2002020740 A2. |
|
|